Abiogen acquires EffRx to fortify bone disease portfolio
Pharmaceutical Technology
MAY 30, 2023
The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland. Separate from drug development, the Italian company also offers contract manufacturing and clinical supply services.
Let's personalize your content